Dedicated Phase I Appoints New CMO
Dedicated Phase I in Phoenix, Ariz., named a new chief medical officer to head its 80-bed phase I clinical research facility. Clark Springgate, M.D., Ph.D., brings more than 25 years' experience to the organization, having directed and participated in more than 256 clinical trials, including first-in-man and first-in-therapeutic-class studies.
"Having Dr. Springgate lead our clinical team furthers our commitment to bringing internationally known research physicians to Dedicated Phase I and Arizona's bioscience community," said Dedicated Phase I's founder and CEO Jason Bonanza.
In other recent personnel news from the clinical trial industry:
WuXi PharmaTech appointed Hao Zhou vice president of finance, responsible for financial planning and analysis, enterprise resource planning implementation, tax and treasury. Zhou worked for General Electric for 11 years before joining WuXi.
INC Research appointed Tom Zoda, Ph.D., as senior vice president of neuropsychiatry to the CRO's central nervous system team. Zoda will oversee all psychiatry and neurology projects on a global basis. Prior to joining INC, Zoda worked for PPD as executive director for Global Strategic Development, CNS.
West Coast Clinical Trials (WCCT) named Thomas Pillsworth, Ph.D., the new vice president of business development. Prior to joining WCCT, Pillsworth was vice president of business development at PharmaNet working in both the early- and late-stage divisions.